当前位置:
X-MOL 学术
›
Bioresour. Bioprocess.
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
Preparation and purification of novel phosphatidyl prodrug and performance modulation of phosphatidyl nanoprodrug
Bioresources and Bioprocessing ( IF 4.3 ) Pub Date : 2019-11-01 , DOI: 10.1186/s40643-019-0277-1 Rui Niu , PeiLei Zhang , Feng-Qing Wang , Min Liu , QingHai Liu , Ning Jia , ShengLi Yang , XinYi Tao , DongZhi Wei
中文翻译:
新型磷脂酰前药的制备与纯化及磷脂酰纳米前药的性能调节
更新日期:2019-11-01
Bioresources and Bioprocessing ( IF 4.3 ) Pub Date : 2019-11-01 , DOI: 10.1186/s40643-019-0277-1 Rui Niu , PeiLei Zhang , Feng-Qing Wang , Min Liu , QingHai Liu , Ning Jia , ShengLi Yang , XinYi Tao , DongZhi Wei
Background
A novel phosphatidyl nanoprodrug system can be selectively released parent drugs in cancer cells, triggered by the local overexpression of phospholipase D (PLD). This system significantly reduces the intrinsic disadvantages of conventional chemotherapeutic drugs. However, the separation and purification processes of phosphatidyl prodrug, the precursor of phosphatidyl nanoprodrug, have not been established, and the preparation of nanocrystals with good stability and tumor-targeting capability is still challenging.Results
In this study, we established a successive elution procedure for the phosphatidyl prodrug—phosphatidyl mitoxantrone (PMA), using an initial ten-bed volume of chloroform/methanol/glacial acetic acid/water (26/10/0.8/0.7) (v/v/v/v) followed by a five-bed volume (26/10/0.8/3), with which purity rates of 96.93% and overall yields of 50.35% of PMA were obtained. Moreover, to reduce the intrinsic disadvantages of conventional chemotherapeutic drugs, phosphatidyl nanoprodrug—PMA nanoprodrug (NP@PMA)—was prepared. To enhance their stability, nanoparticles were modified with polyethylene glycol (PEG). We found that nanoprodrugs modified by PEG (NP@PEG–PMA) were stably present in RPMI-1640 medium containing 10% FBS, compared with unmodified nanoprodrug (NP@PMA). To enhance active tumor-targeting efficiency, we modified nanoparticles with an arginine-glycine-aspartic acid (RGD) peptide (NP@RGD–PEG–PMA). In vitro cytotoxicity assays showed that, compared with the cytotoxicity of NP@PEG–PMA against tumor cells, that of NP@RGD–PEG–PMA was enhanced. Thus, RGD modification may serve to enhance the active tumor-targeting efficiency of a nanoprodrug, thereby increasing its cytotoxicity.Conclusions
A process for the preparation and purification of novel phosphatidyl prodrugs was successfully established, and the nanoprodrug was modified using PEG for enhanced nanoparticle stability, and using RGD peptide for enhanced active tumor-targeting efficiency. These procedures offer considerable potential in the development of functional antitumor prodrugs.中文翻译:
新型磷脂酰前药的制备与纯化及磷脂酰纳米前药的性能调节